Table 3. Virologic evaluation after CTL... | American Society of Hematology

Table 3.

Virologic evaluation after CTL infusion

Patient no.	Virologic findings	Before CTL infusion	After CTL infusion^3-150
1	EA mRNA	Positive	Negative
	EBV-antigenemia	Positive	Negative
	Anti-VCA	>1:640	1:160
	Anti-EBNA	Negative	N/A
2	Anti-VCA	1:640	1:80
	Anti-EBNA	Negative	1:20
3	Anti-VCA	1:640	1:80
	Anti-EBNA	1:5	1:5
	EBV-DNA	97	0
4	Anti-VCA	1:640	1:80
	Anti-EBNA	Negative	1:40
5	Anti-VCA	1:1280	1:160
	Anti-EBNA	Negative	1:80

Patient no.	Virologic findings	Before CTL infusion	After CTL infusion^3-150
1	EA mRNA	Positive	Negative
	EBV-antigenemia	Positive	Negative
	Anti-VCA	>1:640	1:160
	Anti-EBNA	Negative	N/A
2	Anti-VCA	1:640	1:80
	Anti-EBNA	Negative	1:20
3	Anti-VCA	1:640	1:80
	Anti-EBNA	1:5	1:5
	EBV-DNA	97	0
4	Anti-VCA	1:640	1:80
	Anti-EBNA	Negative	1:40
5	Anti-VCA	1:1280	1:160
	Anti-EBNA	Negative	1:80

CTL indicates cytotoxic T lymphocytes; EA mRNA, early antigen messenger RNA; VCA, anti–viral capsid antigen (IgG); EBNA, anti-EBV nuclear antigen (IgG); and N/A, not available.

F3-150

Evaluation performed 2 weeks after the adoptive transfer. Data were reconfirmed at the 4-week post-CTL infusion follow-up evaluation.

View Large